Search Results - "Kotecha, R."

Towards individualized therapy for metastatic renal cell carcinoma by Kotecha, Ritesh R., Motzer, Robert J., Voss, Martin H.

“…Over the past decade, the treatment landscape for patients with metastatic renal cell carcinoma (RCC) has evolved dramatically. The therapeutic options…”
Get full text

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors by Shah, A.Y., Kotecha, R.R., Lemke, E.A., Chandramohan, A., Chaim, J.L., Msaouel, P., Xiao, L., Gao, J., Campbell, M.T., Zurita, A.J., Wang, J., Corn, P.G., Jonasch, E., Motzer, R.J., Sharma, P., Voss, M.H., Tannir, N.M.

“…Immune checkpoint inhibitors (ICIs) are being increasingly utilised in the front-line (1L) setting of metastatic clear-cell renal cell carcinoma (mccRCC)…”
Get full text

Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma by Gleeson, Jack P, Nikolovski, Ines, Dinatale, Renzo, Zucker, Mark, Knezevic, Andrea, Patil, Sujata, Ged, Yasser, Kotecha, Ritesh R, Shapnik, Natalie, Murray, Samuel, Russo, Paul, Coleman, Jonathan, Lee, Chung Han, Stadler, Zsofia K, Hakimi, A Ari, Feldman, Darren R, Motzer, Robert J, Reznik, Ed, Voss, Martin H, Chen, Ying-Bei, Carlo, Maria I

“…Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare, aggressive form of RCC associated with hereditary leiomyomatosis and RCC syndrome…”
Get full text

A clinical study of rhino-orbital-cerebral mucormycosis during the COVID-19 pandemic in western Maharashtra by Manade, Varsha Vivek, Kotecha, Megha R

“…The aim of the study was to describe the epidemiology and study the risk factors, clinical presentation, management, and outcome of rhino-orbital-cerebral…”
Get full text

Update on the Management of Brain Metastasis by Singh, Karanvir, Saxena, Shreya, Khosla, Atulya A., McDermott, Michael W., Kotecha, Rupesh R., Ahluwalia, Manmeet S.

“…Brain metastases occur in almost one-third of adult patients with solid tumor malignancies and lead to considerable patient morbidity and mortality. The rising…”
Get full text

Prognostic Factors for Survival in Patients Undergoing Surveillance After Cytoreductive Nephrectomy by Reese, Stephen W, Khaleel, Sari, Silagy, Andrew, Xie, Amy, Eismann, Lennert, Vazquez-Rivera, Katiana, Oparanozie, Arnold, Patil, Sujata, Coleman, Jonathan, Motzer, Robert, Kotecha, Ritesh R, Russo, Paul, Voss, Martin H, Hakimi, A Ari

“…The clinical course of patients being placed on surveillance in a cohort of systemic therapy-naïve patients who undergo cytoreductive nephrectomy is not well…”
Get full text

Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression by Marcon, Julian, DiNatale, Renzo G, Sanchez, Alejandro, Kotecha, Ritesh R, Gupta, Sounak, Kuo, Fengshen, Makarov, Vladimir, Sandhu, Amar, Mano, Roy, Silagy, Andrew W, Blum, Kyle A, Nassau, Daniel E, Benfante, Nicole E, Ortiz, Michael V, Carlo, Maria I, Chan, Timothy A, Motzer, Robert J, Voss, Martin H, Coleman, Jonathan, Russo, Paul, Reuter, Victor, Hakimi, A Ari, Reznik, Ed

“…Translocation renal cell carcinoma (tRCC) is a rare, aggressive renal cell carcinoma (RCC) subtype. There is currently limited understanding on the role of…”
Get full text

Deciphering radiological stable disease to immune checkpoint inhibitors by Luo, J., Wu, S., Rizvi, H., Zhang, Q., Egger, J.V., Osorio, J.C., Schoenfeld, A.J., Plodkowski, A.J., Ginsberg, M.S., Callahan, M.K., Maher, C., Shoushtari, A.N., Postow, M.A., Voss, M.H., Kotecha, R.R., Gupta, A., Raja, R., Kris, M.G., Hellmann, M.D.

“…‘Stable disease (SD)’ as per RECIST is a common but ambiguous outcome in patients receiving immune checkpoint inhibitors (ICIs). This study aimed to…”
Get full text

Multi-institutional competing risks analysis of distant brain failure and salvage patterns after upfront radiosurgery without whole brain radiotherapy for brain metastasis by McTyre, E., Ayala-Peacock, D., Contessa, J., Corso, C., Chiang, V., Chung, C., Fiveash, J., Ahluwalia, M., Kotecha, R., Chao, S., Attia, A., Henson, A., Hepel, J., Braunstein, S., Chan, M.

“…In this study, we use a competing risks analysis to assess factors predictive of early-salvage whole brain radiotherapy (WBRT) and early death after upfront…”
Get full text

Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape by Golkaram, Mahdi, Kuo, Fengshen, Gupta, Sounak, Carlo, Maria I, Salmans, Michael L, Vijayaraghavan, Raakhee, Tang, Cerise, Makarov, Vlad, Rappold, Phillip, Blum, Kyle A, Zhao, Chen, Mehio, Rami, Zhang, Shile, Godsey, Jim, Pawlowski, Traci, DiNatale, Renzo G, Morris, Luc G T, Durack, Jeremy, Russo, Paul, Kotecha, Ritesh R, Coleman, Jonathan, Chen, Ying-Bei, Reuter, Victor E, Motzer, Robert J, Voss, Martin H, Liu, Li, Reznik, Ed, Chan, Timothy A, Hakimi, A Ari

“…Intratumoral heterogeneity (ITH) is a hallmark of clear cell renal cell carcinoma (ccRCC) that reflects the trajectory of evolution and influences clinical…”
Get full text

Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol by Stutterheim, J., de Lorenzo, P., van der Sluis, I.M., Alten, J., Ancliffe, P., Attarbaschi, A., Aversa, L., Boer, J.M., Biondi, A., Brethon, B., Diaz, P., Cazzaniga, G., Escherich, G., Ferster, A., Kotecha, R.S., Lausen, B., Leung, Alex WK, Locatelli, F., Silverman, L., Stary, J., Szczepanski, T., van der Velden, V.H.J., Vora, A., Zuna, J., Schrappe, M., Valsecchi, M.G., Pieters, R.

“…The outcome of infants with KMT2A-germline acute lymphoblastic leukaemia (ALL) is superior to that of infants with KMT2A-rearranged ALL but has been inferior…”
Get full text

Prophylactic Radiotherapy Of MInimally Symptomatic Spinal Disease (PROMISSeD): study protocol for a randomized controlled trial by Rothrock, Robert J, Ozair, Ahmad, Avendano, Maria C, Herrera, Susana, Appel, Haley, Ramos, Suyen, Starosciak, Amy K, Leon-Ariza, Daniel S, Rubens, Muni, McDermott, Michael W, Ahluwalia, Manmeet S, Mehta, Minesh P, Kotecha, Rupesh R

“…Early palliative/pre-emptive intervention improves clinical outcomes and quality of life for patients with metastatic cancer. A previous signal-seeking…”
Get full text

Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin by Cruickshank, M N, Ford, J, Cheung, L C, Heng, J, Singh, S, Wells, J, Failes, T W, Arndt, G M, Smithers, N, Prinjha, R K, Anderson, D, Carter, K W, Gout, A M, Lassmann, T, O'Reilly, J, Cole, C H, Kotecha, R S, Kees, U R

“…To address the poor prognosis of mixed lineage leukemia (MLL)-rearranged infant acute lymphoblastic leukemia (iALL), we generated a panel of cell lines from…”
Get full text

Regression of Intracranial Meningiomas Following Treatment with Cabozantinib by Kotecha, Rupesh, Tonse, Raees, Appel, Haley, Odia, Yazmin, Kotecha, Ritesh R, Rabinowits, Guilherme, Mehta, Minesh P

“…Recurrent meningiomas remain a substantial treatment challenge given the lack of effective therapeutic options aside from surgery and radiation therapy, which…”
Get full text

Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma by Tourigny, David S., Zucker, Mark, Kim, Minsoo, Russo, Paul, Coleman, Jonathan, Lee, Chung-Han, Carlo, Maria I., Chen, Ying-Bei, Hakimi, A. Ari, Kotecha, Ritesh R., Reznik, Ed

“…Renal medullary carcinoma (RMC) is a highly aggressive disease associated with sickle hemoglobinopathies and universal loss of the tumor suppressor gene…”
Get full text

DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy by Ged, Yasser, Chaim, Joshua L, DiNatale, Renzo G, Knezevic, Andrea, Kotecha, Ritesh R, Carlo, Maria I, Lee, Chung-Han, Foster, Ashley, Feldman, Darren R, Teo, Min Yuen, Iyer, Gopakumar, Chan, Timothy, Patil, Sujata, Motzer, Robert J, Hakimi, A Ari, Voss, Martin H

“…BackgroundLoss-of-function alterations in DNA damage repair (DDR) genes are associated with human tumorigenesis and may determine benefit from immune-oncology…”
Get full text

A qualitative framework of non-selection factors for cytoreductive nephrectomy by Silagy, Andrew W., Attalla, Kyrollis, Dinatale, Renzo G., Weiss, Kate L., Weng, Stanley, Mano, Roy, Iosepovici, Skylar, Marcon, Julian, Reznik, Ed, Kotecha, Ritesh R., Motzer, Robert J., Voss, Martin H., Coleman, Jonathan A., Hakimi, A. Ari, Russo, Paul

“…Purpose Cytoreductive nephrectomy (CN) benefits a subset of patients with metastatic renal cell carcinoma (mRCC), however proper patient selection remains…”
Get full text

Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia by Mateos, M.K., Trahair, T.N., Mayoh, C., Barbaro, P.M., Sutton, R., Revesz, T., Barbaric, D., Giles, J.E., Alvaro, F., Mechinaud, F., Catchpoole, D., Kotecha, R.S., Dalla-Pozza, L., Quinn, M.C.J., MacGregor, S., Chenevix-Trench, G., Marshall, G.M.

“…Symptomatic venous thromboembolism (VTE) is an unpredictable and life-threatening toxicity, which occurs early in childhood acute lymphoblastic leukemia (ALL)…”
Get full text

Acute Leukaemia of Ambiguous Lineage Presenting as a Focal Bone Lesion: a Case Report by Yi, H, Dhamija, M, Dholaria, H, Kotecha, R, Roebuck, D

“…Magnetic resonance imaging (MRI) of the thighs showed numerous other focal bone lesions, all asymptomatic (Figure 2), and CT of the chest and abdomen showed no…”
Get full text

The evolution of clinical trials for infant acute lymphoblastic leukemia by Kotecha, R S, Gottardo, N G, Kees, U R, Cole, C H

“…Acute lymphoblastic leukemia (ALL) in infants has a significantly inferior outcome in comparison with older children. Despite initial improvements in survival…”
Get full text